LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 1 of total 1

Search options

Article ; Online: Higher heparin dosages reduce thromboembolic complications in patients with COVID-19 pneumonia.

Carallo, Claudio / Pugliese, Fabiola / Vettorato, Elisa / Tripolino, Cesare / Delle Donne, Livia / Guarrera, Giovanni / Spagnolli, Walter / Cozzio, Susanna

Journal of investigative medicine : the official publication of the American Federation for Clinical Research

2021  

Abstract: ... of adult patients hospitalized for COVID-19 pneumonia, never underwent to oropharyngeal intubation ... might request higher enoxaparin doses to reduce thromboembolic events in hospitalized patients, even if outside ... of body weight in the prevention of clot complications in COVID-19 pneumonia. Retrospective data from a cohort ...

Abstract Coronavirus disease 2019 (COVID-19) is a new viral disease complicating with acute thrombophylic conditions, probably also via an inflammatory burden. Anticoagulants are efficacious, but their optimal preventive doses are unknown. The present study was aimed to compare different enoxaparin doses/kg of body weight in the prevention of clot complications in COVID-19 pneumonia. Retrospective data from a cohort of adult patients hospitalized for COVID-19 pneumonia, never underwent to oropharyngeal intubation before admission, were collected in an Internal Medicine environments equipped for non-invasive ventilation. Unfavorable outcomes were considered as: deep venous thrombosis, myocardial infarction, stroke, pulmonary embolism, cardiovascular death. Fourteen clinical thromboembolic events among 42 hospitalized patients were observed. Patients were divided into two group on the basis of median heparin dose (0.5 mg-or 50 IU-for kg). The decision about heparin dosing was patient by patient. Higher enoxaparin therapy (mean 0.62±0.16 mg/kg) showed a better thromboprophylactic action (HR=0.2, p=0.04) with respect to lower doses (mean 0.42±0.06 mg/kg), independently from the clinical presentation of the disease. Therefore, COVID-19 pneumonia might request higher enoxaparin doses to reduce thromboembolic events in hospitalized patients, even if outside intensive care units.
Language English
Publishing date 2021-03-23
Publishing country England
Document type Journal Article
ZDB-ID 1217870-6
ISSN 1708-8267 ; 0009-9279 ; 1081-5589
ISSN (online) 1708-8267
ISSN 0009-9279 ; 1081-5589
DOI 10.1136/jim-2020-001628
Shelf mark
Zs.A 307: Show issues Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)
Database MEDical Literature Analysis and Retrieval System OnLINE

More links

Kategorien

To top